Indoco Remedies is India based Pharmaceuticals company, will announce its first quarter financial results today, Jul. 30, 2015.

Commenting on the quarterly results, Angel Broking said, ''Indoco Remedies, for its 1QFY2016 results, is expected to post a 28.3% yoy growth in sales on top line to end the period at Rs 2.54 billion, mainly driven by exports. The EBDITA margins consequently are expected to come in at 18.0% v/s 18.1% in 1QFY2015, inspite of higher R&D expenditure mainly driven by robust sales growth.

R&D expenditure during the quarter is expected to be 3.5% of sales V/s 2.2% of sales in 1QFY2015. Consequently, the PAT is expected to come in at Rs 270 million V/s Rs 200 million in 1QFY2015, a growth of 34.5% yoy. We maintain our neutral rating on the stock, on back of valuations.''

Shares of the company gained Rs 0.5, or 0.14%, to trade at Rs 369.30. The total volume of shares traded was 761 at the BSE (10.19 a.m., Thursday).